<DOC>
	<DOCNO>NCT03042611</DOCNO>
	<brief_summary>The purpose study evaluate clinical benefit safety Apatinib plus Best Supportive Care comparison Placebo plus Best Supportive Care patient advance metastatic gastric cancer</brief_summary>
	<brief_title>Efficacy Safety Trial Apatinib Plus Best Supportive Care Compared Placebo Plus Best Supportive Care Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Male female ≥ 18 year age . 2 . Documented primary diagnosis histologic cytologicconfirmed adenocarcinoma stomach gastroesophageal junction . 3 . Locally advanced unresectable metastatic disease progress since last treatment . 4 . One measurable nonmeasurable evaluable lesion per RECIST 1.1 . 5 . Failure intolerance least two prior line standard chemotherapy contain one follow agent : fluoropyrimidine ( IV 5FU capecitabine , S1 ) , platinum ( cisplatin oxaliplatin ) , taxanes ( paclitaxel docetaxel ) epirubicin , irinotecan , trastuzumab case HER2positive ramucirumab 6 . Disease progression within 6 month last treatment . 7 . Adequate bonemarrow , renal liver function . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 . 9 . Expected survival ≥ 12 week , opinion investigator . 10 . Ability swallow investigational product tablet . 11 . Female patient negative pregnancy test Screening use acceptable method birth control study duration , unless surgically sterile postmenopausal least 1 year prior Screening . 12 . Ability willingness comply study protocol duration study followup procedure . 1 . Malignancies adenocarcinoma stomach gastroesophageal junction ( include hematologic malignancy ) within 3 year . 2 . CNS metastases show radiology record clinical evidence symptomatic CNS involvement last 3 month prior randomization . 3 . Cytotoxic chemotherapy , surgery , immunotherapy , radiotherapy target therapy within 4 week ( 6 week case ramucirumab , mitomycin C , nitrosourea , lomustine ; 2 week case biopsy ) prior randomization ( Adjuvant radiotherapy give local area noncurative symptom relief allow 2 week randomization. ) . 4 . Therapy clinically significant systemic anticoagulant antithrombotic agent within 7 day prior randomization may prevent blood clotting , investigator 's opinion , could place subject risk . 5 . Patients therapeutic paracentesis ascites ( &gt; 1L ) within 3 month prior start study treatment , opinion investigator , likely need therapeutic paracentesis ascites ( &gt; 1L ) within 3 month start study treatment . 6 . Previous treatment Apatinib . 7 . Known hypersensitivity Apatinib component formulation . 8 . Concomitant treatment strong inhibitor inducer CYP3A4 , CYP2C9 CYP2C19 . 9 . Active bacterial infection . 10 . Substance abuse medical , psychological , social condition may interfere patient 's participation study evaluation study result . 11 . Participation clinical trial within 4 week prior randomization . 12 . Pregnant breastfeed woman . 13 . History drug alcohol abuse within past 5 year . 14 . Medical psychiatric illness , investigator 's opinion , may impact safety subject objective study . 15 . History uncontrolled hypertension ( Blood pressure ≥ _140/90 mmHg change antihypertensive medication within 7 day prior randomization ) well manage medication risk may precipitate VEGF inhibitor therapy . 16 . Known history symptomatic congestive heart failure ( New York Heart Association IIIIV ) , symptomatic poorly control cardiac arrhythmia , complete leave bundle branch block , bifascicular block , clinically significant ST segment and/or Twave abnormality , QTcF &gt; 450 msec prior randomization . 17 . Prior major surgery fracture within 3 week prior randomization presence nonhealing wound . 18 . History bleed diathesis clinically significant bleeding within 14 day prior randomization . 19 . History clinically significant thrombosis within past 3 month prior randomization , investigator 's opinion , may place patient risk side effect antiangiogenesis product . 20 . History gastrointestinal bleeding , gastric stress ulceration , peptic ulcer disease within past 3 month prior randomization , investigator 's opinion , may place patient risk side effect antiangiogenesis product . 21 . Myocardial infarction unstable angina pectoris within 6 month prior randomization . 22 . History severe adverse event , investigator 's opinion , related ramucirumab . 23 . History significant cardiovascular disease vascular disease within last 6 month prior randomization , investigator 's opinion , may pose risk patient VEGF inhibitor therapy . 24 . History clinically significant glomerulonephritis , biopsyproven tubulointerstitial nephritis , crystal nephropathy , renal insufficiency . 25 . Gastrointestinal malabsorption , condition opinion investigator might affect absorption study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Gastric Adenocarcinoma</keyword>
	<keyword>Gastro-esophageal Cancer</keyword>
	<keyword>Gastro-esophageal junction Cancer</keyword>
	<keyword>Stomach Cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Oncology</keyword>
	<keyword>Antiangiogenesis</keyword>
	<keyword>Metastatic</keyword>
</DOC>